Companies /Healthcare

Corvus Pharmaceuticals Inc

NASDAQ: CRVS Biotechnology
$9.67
▼ $0.34 (−3.40%) today
Markets closed · 12:54pm ET

CRVS at a Glance

Valuation
Market cap
$815.7M
Profitability
EPS (TTM)
$-0.72
Price
52-week range
$6 – $27
Street target
$31.50

Headquartered in South San Francisco, CA Fiscal year ends December NASDAQ: CRVS corvuspharma.com

About Corvus Pharmaceuticals

Corvus Pharmaceuticals is a clinical-stage, pre-revenue biopharmaceutical company developing ITK (interleukin-2-inducible T cell kinase) inhibition as a new approach to immunotherapy for immune diseases and cancer.

Its lead candidate, soquelitinib (formerly CPI-818), is an investigational oral small molecule that selectively inhibits ITK. It is being evaluated in:
- a registrational Phase 3 trial in relapsed/refractory peripheral T cell lymphoma, where it holds Orphan Drug and Fast Track designations;
- the SIERRA1 Phase 2 trial in atopic dermatitis;
- a Phase 1b trial in hidradenitis suppurativa;
- an NIAID-collaboration Phase 2 trial in autoimmune lymphoproliferative syndrome;
- a planned Phase 2 trial in asthma.

Corvus also advances next-generation preclinical ITK inhibitors. Its other clinical-stage candidates, ciforadenant and mupadolimab, are being developed for cancer indications.

The company holds a 49% equity stake in Angel Pharmaceuticals, a privately held China-focused biotech. Angel licensed rights to soquelitinib, ciforadenant and mupadolimab in greater China and holds global rights to Corvus' preclinical BTK inhibitor programs. Updated

Latest Activity

CRVSCorvus Pharmaceuticals
Q3 2026
EPS
-$0.22
est -$0.20-7.3%
Revenue
$0K

R&D spending more than doubled to $17.8 million as Corvus pushes soquelitinib into lymphoma, eczema, hidradenitis suppurativa and now asthma, widening the loss past consensus. The $202.9 million cash pile funds operations into the second quarter of 2028, which covers the 2027 readouts that decide this story.

Quarterly EPS — reported vs estimate

CRVS Coverage

9:27am ET
Investing

3 Penny Stocks Wall Street Sees With 243% Upside

Penny stocks captivate investors with their low prices. The allure of controlling large numbers of shares for relatively very little money, and potentially generating explosive gains if their stocks move just a…

Rich Duprey

Frequently Asked Questions

What does Corvus Pharmaceuticals do?

Corvus Pharmaceuticals is a clinical-stage, pre-revenue biopharmaceutical company developing ITK (interleukin-2-inducible T cell kinase) inhibition as a new approach to immunotherapy for immune diseases and cancer.

What is the CRVS stock price target?

The Wall Street consensus 12-month price target for CRVS is $31.50.